CBD & Diabetes

According to The Diabetes Council, the correlation between cannabis and the treatment of the symptoms of Type 1 and Type 2 diabetes, as well as pre-diabetes, may lie in anti-inflammatory capabilities of cannabinoids. According to cannabisMD.com, research that has been conducted has implied that the use of cannabis may help with stabilizing blood sugars, preventing nerve inflammation, lowering blood pressure over time, keeping blood vessels opened and improving circulation. Research has also found that cannabinoids may be more effective than existing diabetes medication.

For people with Type 1 diabetes, The Diabetes Council research has found that CBD can reduce the occurrence and delay of the onset of the disease. Furthermore,

In marijuana, the THC enzyme has been found to suppress the autoimmune response of the disease, reducing the amount of insulin needed during treatment. People suffering from Type 2 diabetes that use CBD may fix an endocannabinoid imbalance that makes it harder for people to lose weight, which is an important step in treating Type 2.  CBD may also help reduce insulin resistance, the crucial mechanism that causes the disease to progress.

The anti-inflammatory properties of cannabis may be critical to helping treat the secondary symptoms of the disease, including heart problems, pain, and eye issues. Research from the American Alliance for Medical Cannabis (AAMC) found other benefits from cannabis use on secondary symptoms, including:

  • A “neuroprotective” effect that can reduce nerve pain
  • “Anti-spasmodic agents” that can relieve GI cramping and pain
  • A “vasodilator” effect that can improve circulation
  • Calming of diabetic “restless leg syndrome” that can help people sleep better

To discuss any of these findings please contact us

*Disclaimer
The content on these pages are in no way intended to offer any related health benefits to our products but merely to share opinions and any research findings.

Go to our CBD Shop

Golden Extracts CBD Oil UK Spain Europe

sources:
Forbes